Extracellular signal-regulated kinases 1/2 (ERK1/2) are central components of the MAPK signaling cascade, regulating cell growth, survival, and differentiation. Activated by MEK1/2 through phosphorylation, ERK1/2 phosphorylate diverse cytoplasmic and nuclear targets. ERK1/2 dysregulation is associated with cancer, driving tumor proliferation and resistance to therapy, and with neurodegenerative diseases like Alzheimer's, where it influences amyloid plaque formation.
The AlphaLISA SureFire Biotin-Free Human and Mouse Total ERK1/2 Detection Kit is a sandwich immunoassay for the quantitative detection of total ERK1/2 in cellular lysates, using Alpha Technology.
Formats:
The HV (high volume) kit contains reagents to run 100 wells in 96-well format, using a 60 μL reaction volume.
The 500-point kit contains enough reagents to run 500 wells in 384-well format, using a 20 μL reaction volume.
The 10,000-point kit contains enough reagents to run 10,000 wells in 384-well format, using a 20 μL reaction volume.
The 50,000-point kit contains enough reagents to run 50,000 wells in 384-well format, using a 20 μL reaction volume.
AlphaLISA SureFire Biotin Free kits are compatible with:
Cell and tissue lysates
Antibody modulators
Biotherapeutic antibodies
Biotin rich samples
AlphaLISA SureFire Biotin Free kits can be used for:
Cellular kinase assays
Receptor activation studies
High-throughput screening for preclinical studies
Total-AlphaLISA SureFire Biotin Free assay principle
The Total-AlphaLISA SureFire Biotin Free assay measures the expression level of a target protein in a biological sample (e.g. cell lysate).
The Total-AlphaLISA SureFire Biotin Free assay uses two antibodies which recognize two different distal epitopes on the target protein. AlphaLISA assays require two bead types: Acceptor and Donor Beads. Acceptor Beads are coated with a proprietary CaptSure™ agent to specifically immobilize the assay specific antibody, labeled with a CaptSure tag. Donor Beads are coated with a proprietary CaptSure3 agent to capture one of the detection antibodies, which is labeled with the CaptSure3 tag. In the presence of target protein, the two antibodies bring the Donor and Acceptor Beads in close proximity whereby the singlet oxygen transfers energy to excite the Acceptor Bead, allowing for the generation of a luminescent Alpha signal. The amount of light emission is directly proportional to the quantity of protein present in the sample.
Total-AlphaLISA SureFire Biotin Free two-plate assay protocol
The two-plate protocol involves culturing and treating the cells in a 96-well plate before lysis, then transferring lysates into a 384-well OptiPlate™ plate before the addition of Total-AlphaLISA SureFire Biotin Free detection reagents. This protocol enables cell viability and confluence to be monitored. In addition, lysates from a single well can be used to measure multiple targets.
Total-AlphaLISA SureFire Biotin Free one-plate assay protocol
Detection of Total target protein with AlphaLISA SureFire Biotin Free reagents can be performed in a single plate used for culturing, treatment, and lysis. No washing steps are required. This HTS designed protocol allows for miniaturization while maintaining robust AlphaLISA SureFire quality.
Validation of Phospho (Thr202/Tyr204)/Total ERK1/2 in PMA treated cells
Jurkat cells were seeded in a 96-well plate (200,000 cells/well) in complete RPMI 1640 medium and treated with increasing concentrations of PMA for 15 minutes.
After treatment, the cells were lysed with the addition of 50 µL of 5X Lysis Buffer for 10 minutes at RT with shaking (350 rpm). ERK1/2 Phospho (Thr202/Tyr204) and Total levels were evaluated using respective AlphaLISA SureFire Biotin Free assays. For the detection step, 10 µL of cell lysate (approximately 8,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, PMA triggered a dose-dependent increase in the levels of Phospho ERK1/2 (Thr202/Tyr204) while Total ERK1/2 levels remained unchanged.
Validation of Phospho (Thr202/Tyr204)/Total ERK1/2 in Anti-CD3 treated cells
Jurkat cells were seeded in a 96-well plate (200,000 cells/well) in serum-free RPMI 1640 medium. The cells were starved for 1 hour and then treated with increasing concentrations of Anti-CD3 antibody for 5 minutes. After treatment, the cells were lysed with the addition of 50 µL of 5X Lysis Buffer for 10 minutes at RT with shaking (350 rpm). ERK1/2 Phospho (Thr202/Tyr204) and Total levels were evaluated using respective AlphaLISA SureFire Biotin Free assays. For the detection step, 10 µL of cell lysate (approximately 8,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, Anti-CD3 triggered a dose-dependent increase in the levels of Phospho ERK1/2 (Thr202/Tyr204) while Total ERK1/2 levels remained unchanged.
Validation of Phospho (Thr202/Tyr204)/Total ERK1/2 in Anti-IgM treated cells
Ramos cells were seeded in a 96-well plate (200,000 cells/well) in serum free RPMI 1640 medium. The cells were starved for 1 hour and then treated with increasing concentrations of Anti-IgM for 20 minutes. After treatment, the cells were lysed with the addition of 50 µL of 5X Lysis Buffer for 10 minutes at RT with shaking (350 rpm). ERK1/2 Phospho (Thr202/Tyr204) and Total levels were evaluated using respective AlphaLISA SureFire Biotin Free assays. For the detection step, 10 µL of cell lysate (approximately 8,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
Treatment with Anti-IgM triggered a dose-dependent increase in the levels of Phospho ERK1/2 (Thr202/Tyr204) while Total ERK1/2 levels remained unchanged.
Validation of Phospho (Thr202/Tyr204)/Total ERK1/2 in AG1478 treated cells
PC3 cells were seeded in a 96-well plate (40,000 cells/well) in complete Ham’s F-12K (Kaighn’s) medium and incubated overnight at 37°C, 5% CO2. The cells were treated for 2 hours with increasing concentrations of AG1478 and then stimulated with 1 ng/mL of EGF for 30 minutes.After treatment, the cells were lysed with 200 µL of Lysis Buffer for 10 minutes at RT with shaking (350 rpm). ERK1/2 Phospho (Thr202/Tyr204) and Total levels were evaluated using respective AlphaLISA SureFire Biotin Free assays. For the detection step, 10 µL of cell lysate (approximately 4,000 cells) was transferred into a 384-well white OptiPlate, followed by 5 µL of Acceptor mix and incubated for 1 hour at RT. Finally, 5 µL of Donor mix was then added to each well and incubated for 1 hour at RT in the dark. The plate was read on an Envision using standard AlphaLISA settings.
As expected, AG1478 triggered a dose-dependent decrease in the levels of Phospho ERK (Thr202/Tyr204) while Total ERK1/2 levels remained unchanged.
